摘要
目的探讨阿帕替尼三线治疗广泛期小细胞肺癌(ES-SCLC)的有效性及安全性。方法选取2020年1月至2021年1月中国人民解放军联勤保障部队第九八〇医院收治的50例ES-SCLC患者为研究对象,根据治疗药物的不同分为阿帕替尼组(试验组,27例)和安慰剂组(对照组,23例)。试验组给予阿帕替尼250 mg/d口服,直至疾病进展或不良反应不可耐受,对照组给予安慰剂治疗。观察中位无进展生存(PFS)、客观缓解率(ORR)、疾病控制率(DCR)及不良反应发生率。结果试验组治疗时间1.5~12.0个月,完全缓解0例,部分缓解4例,疾病稳定13例,疾病进展10例,中位PFS为4.0个月,ORR为14.8%,DCR为63.0%。试验组较对照组PFS(0.9个月)延长了3.1个月,疾病进展或死亡风险下降62%(HR=0.38,95%CI:0.20~0.73,P<0.05)。试验组治疗期间不良反应主要为高血压、蛋白尿、手足综合征,均为1~2级,予以对症治疗可耐受。结论阿帕替尼三线治疗ES-SCLC有效、安全。
Objective To investigate the efficacy and safety of apatinib in the third-line treatment of extensive-stage small cell lung cancer(ES-SCLC).Methods A total of 50 patients with ES-SCLC in this hospital from January 2020 to January 2021 were collected,and were divided into the apatinib group(the experimental group,27 cases)and the placebo group(the control group,23 cases)according to different therapeutic drugs.The experimental group was given apatinib 250 mg/d orally until the disease progressed or adverse reactions became intolerable,while the control group was given placebo.The median progression-free survival(PFS),the objective response rate(ORR),disease control rate(DCR)and adverse reactions were observed.Results The treatment time of experimental group was 1.5-12.0 months,there were 0 cases of complete remission,4 cases of partial remission,13 cases of stable disease and 10 cases of progressive disease.The median PFS was 4.0 months,the ORR and DCR were 14.8%and 63.0%,respectively.The median PFS in the experimental group was 3.1 months longer than that in the control group(0.9 months),and the risk of disease progression or death was reduced by 62%(HR=0.38,95%CI:0.20-0.73,P<0.05).During the treatment,the common adverse reactions in the experimental group were hypertension,proteinuria and hand-foot syndrome,which were all level 1-2 and could be tolerated by symptomatic treatment.Conclusion Apatinib is safe and effective in the third-line treatment of ES-SCLC.
作者
李铁钢
崔志强
LI Tiegang;CUI Zhiqiang(Department of Oncology,the 980th Hospital of Chinese PLA Joint Logistics Support Forces,Shijiazhuang,Hebei 050082,China;The First Department of Breast Surgery,Affiliated Hospital of Hebei Engineering University,Handan,Hebei 056000,China)
出处
《重庆医学》
CAS
2023年第17期2606-2609,共4页
Chongqing medicine
基金
河北省石家庄市科学技术研究与发展计划项目(201200643)。
关键词
小细胞肺癌
神经内分泌癌
抗血管生成
阿帕替尼
分子靶向治疗
small-cell lung cancer
neuroendocrine carcinoma
anti-angiogenesis
apatinib
molecular targeted therapy
